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Abstract
Background. Sex differences in cognitive functioning have long been recognized in schizophre-
nia patients and healthy controls (HC). However, few studies have focused on patients with an
at-risk mental state (ARMS) for psychosis. Thus, the aim of the present study was to investigate
sex differences in neurocognitive performance in ARMS patients compared with HC.
Methods.The data analyzed in this study were collected within themulticenter EuropeanGene–
Environment Interactions study (11 centers). A total of 343 ARMS patients (158 women) and
67 HC subjects (33 women) were included. All participants completed a comprehensive
neurocognitive battery. Linearmixed effectsmodels were used to explore whether sex differences
in cognitive functioning were present in the total group (main effect of sex) and whether sex
differences were different for HC and ARMS (interaction between sex and group).
Results.Women performed better in social cognition, speed of processing, and verbal learning
than men regardless of whether they were ARMS or HC. However, only differences in speed of
processing and verbal learning remained significant after correction for multiple testing.
Additionally, ARMS patients displayed alterations in attention, current IQ, speed of processing,
verbal learning, and working memory compared with HC.
Conclusions. Findings indicate that sex differences in cognitive functioning inARMS are similar
to those seen between healthy men and women. Thus, it appears that sex differences in cognitive
performance may not be specific for ARMS, a finding resembling that in patients with
schizophrenic psychoses.
Introduction
Sex differences in schizophrenia have been described in almost all features of the illness, including
incidence, prevalence, age at onset, symptomatology, course, and in the response to treatment,
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but only reliably established in age at onset and course [1]. Sex-related
differences in the illness coursemight be at least partiallymediated by
sex-related differences in cognitive functioning [2]. Reduced cognitive
performance is one of the core features of schizophrenia and an
important predictor of outcome [3]. Several studies have shown
neurocognitive deficits already in patients with a so-called at-risk
mental state (ARMS) for psychosis [4]. Furthermore, it has been
found that ARMS patients with later conversion to psychosis per-
formedworse at baseline in testsmeasuring attention/vigilance, speed
of processing, verbal and visual learning, and current and premorbid
IQ compared with patients who did not convert [4]. Consequently,
several studies have shown that the prediction of transition to psy-
chosis can be improved by including neurocognitive performance
measures into multivariable risk prediction models [4–8].
Cognitive performance is not only dependent on different stages
of psychotic disorders, but also on sex. In healthy controls (HC), it
is well established that women tend to perform better than men in
tasks measuring verbal abilities (d= 0.24; for meta-analysis, see
reference [9]), whereas men tend to outperform women on
visual–spatial tasks (d=0.45; for meta-analysis, see [9]) [10–
12]. Most studies indicate that these differences are also maintained
in patients with schizophrenic psychoses (for reviews, see refer-
ences [1,2]). Specifically, many studies have shown that women
diagnosed with schizophrenia have a better performance in verbal
learning and memory [1,13,14]. The female advantage in verbal
domains has also been found in patients with first-episode psycho-
sis (FEP), while men showed a better performance in tests of
reaction time, visual memory, and executive functions [1,10].
The impact of sex on cognitive functioning in ARMS has
received considerable attention in the literature in recent years. A
meta-regression analysis based on 19 studies assessing neuropsy-
chological performance in 1,188 ARMS patients (women, n= 523;
44%) and 1,029 HC (women, n=464; 45%) showed a trend-level
significance effect of sex on cognitive performance, with females
performing relatively better than males [15]. Our own group inves-
tigated sex differences in cognitive functioning in 118 ARMS
patients (women, n=45; 38%), 88 FEP patients (women, n= 32;
36%), and 86 HC (women, n= 41; 47%) [10]. Women performed
better in the domain of verbal learning and memory whereas men
showed a shorter reaction time during the working memory task
across all groups. However, these differences did not withstand
correction for multiple testing. Taken together, existing studies
indicate that female patients with psychotic disorders or being at
clinical high risk for psychosis do not perform better than males
over and above what we see in HC.
To the best of our knowledge, the present study is the first to
investigate sex differences in cognitive functioning in a large mul-
tinational sample of ARMS patients by using an extended neuro-
psychological battery and a healthy comparison group. The goal of
the study was to elucidate whether sex differences in cognitive
functioning differ between ARMS and HC subjects. Based on the
evidence above and our own findings, we expected a better perfor-
mance of women in the domain of verbal learning and memory
irrespective of group.
Methods
Setting and recruitment
The neuropsychological data analyzed in this study were collected
within the EUropean Gene–Environment Interactions (EU-GEI)
study, which aims to identify the interactive genetic, clinical, and
environmental determinants of schizophrenia [16]. EU-GEI is a
naturalistic prospective multicenter study that consisted of a base-
line and up to three follow-up time points (at 6months, 12months,
and 24months). Data were collected from May 1, 2010 to August
6, 2015. For the current analyses, only baseline data, that is, at intake
into the study, were used.
ARMS participants were recruited from 11 Early Detection and
Intervention Centers (London, Amsterdam, The Hague, Vienna,
Basel, Cologne, Copenhagen, Paris, Barcelona, Melbourne, Saõ
Paulo). They were referred to the EU-GEI study by primary health
care services, mental health professionals, or themselves or their
families.
Control participants were recruited by four of the above-
mentioned centers: the Institute of Psychiatry, Psychology, and
Neuroscience (IoPPN) in London, the Personal Assessment and
Crisis Evaluation Clinic inMelbourne, and theAmsterdamMedical
Center and Parnassia, The Hague. They were approached by tele-
phone and through advertisements at educational institutes. In
Melbourne, controls were additionally approached at community
centers/noticeboards and advertised via online platforms. Controls
were matched to the ARMS patients in terms of age, sex, migrant,
and ethnic status. All participants were screened with an inclusion/
exclusion checklist (see below).
The protocol of the EU-GEI study was approved by the institu-
tional review boards of all study sites. EU-GEI was conducted in
accordance with the Declaration of Helsinki. The Medical Ethics
Committees of all participating sites approved the study protocol.
Inclusion and exclusion criteria
Inclusion criteria for ARMS patients were: aged 14–45 (most of
them were between 18 and 35 years); being at-risk for psychosis as
defined by the comprehensive assessment of at-risk mental state
(CAARMS) [17]; adequate language skills corresponding to each
center; and consent to study participation. The exclusion criteria
were: prior experience of a psychotic episode of more than 1-week
as determined by the CAARMS [17] and Structural Clinical Inter-
view for Diagnostic and Statistical Manual of Mental Disorders
(DSMDisorders (SCID)) [18]; previous treatment with an antipsy-
chotic for a psychotic episode; and IQ< 60.
Inclusion criteria for controls were: aged 18–35; adequate lan-
guage skills local to each center; no evidence of current or past
psychosis (including treatment with antipsychotic medication).
Exclusion criteria for controls were similar to those for ARMS
participants. Additionally, controls were excluded if they met the
criteria for an ARMS status as defined by the CAARMS [17].
Detection procedure
The CAARMS was used to identify ARMS patients [17]. The
CAARMS is a semi-structured interview that encompasses psychotic
symptoms and a range of other psychopathological symptoms pre-
sent during the psychosis prodrome. Individuals were classified as
being in an ARMS for psychosis if they met at least one of the
following risk criteria: (i) attenuated psychotic symptoms (psychotic
symptoms subthreshold either in intensity or frequency); (ii) brief
limited psychotic symptoms (recent episode of brief psychotic symp-
toms that spontaneously resolved within 1week); or
(iii) vulnerability group (a first-degree relative with a psychotic
disorder or a diagnosis of a schizotypal personality disorder in
combination with a significant drop in functioning). The full criteria
can be found elsewhere [17].
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Assessment of sociodemographic and clinical characteristics
Sociodemographic characteristics (e.g. age, sex, ethnicity) were
obtained using the modifiedMedical Research Council sociodemo-
graphic schedule [19]. Current cannabis frequency was assessed
with the modified version of the Cannabis Experience Question-
naire [20]. Data on comorbid affective and anxiety disorders were
assessed with the SCID [18]. Psychiatric medication (i.e., use of
antipsychotics, antidepressants, and sedatives) was obtained using
a medical history questionnaire, designed by the EU-GEI group.
The general level of functioning was assessed with the modified
version of the Global Assessment of Functioning (GAF) scale [21].
Classification and assessment of neuropsychology
Neuropsychological performance of each participant was assessed
by trained psychiatrists, psychologists, and research assistants. The
neuropsychological tests covered the following seven domains:
attention/vigilance, reasoning/problem solving, speed of proces-
sing, verbal learning, working memory, social cognition, and cur-
rent IQ. Test scores were assigned to cognitive domains in
accordance with Measurement and Treatment Research to
Improve Cognition in Schizophrenia (MATRICS) Consensus Cog-
nitive Battery (MCCB) [22]. Tests that are not part of the MCCB
were assigned to domains according to their most commonly used
function. The following measures were used to cover the cognitive
domains of interest:
• Attention/vigilance: Digit Span Forward subtest of the Wechsler
Adult Intelligence Scale-third edition (WAIS-III) [23];
• Reasoning/problem solving: Beads Task [24];
• Speed of processing: Digit Symbol Test of the WAIS-III and the
Trail-Making Test parts A and B [25];
• Verbal Learning: Rey Auditory Verbal Learning Test [26];
• Working memory: Digit Span Backwards and Arithmetic sub-
tests of the WAIS-III [23];
• Social cognition: Degraded Affect Recognition Task [27] and the
Benton Facial Recognition Test [28]; and
• Current IQ: Block Design total raw score, the information total
raw score and the estimate of the total IQ of the shortenedWAIS-
III [23,29].
Assessment of psychopathology
The Brief Psychiatric Rating Scale expanded version (BPRS-E) [30]
was used to assess psychopathology. Sex differences were investi-
gated using the BPRS total score and the following subscales: BPRS
positive symptoms and BPRS negative symptoms [31].
Statistical analyses
All statistical analyses were performed using R [32]. Because obser-
vations were nonindependent, that is, observations from the same
center were more similar than observations from different centers,
sex differences were analyzed using linear mixed effects models
including sex and group (ARMS, HC) as a fixed effects factors and
randomly varying intercepts per center to account for the clustering
in the data. Linearmixed effects models were applied to evaluate the
main effects of sex and group (ARMS, HC) as well as their inter-
actions on cognitive functioning. Dependent variables were z-
transformed before inclusion to models and sex was included as a
binary variable with 0 and 1 describing men and women, respec-
tively. Thus, the regression coefficient for sex described the stan-
dardized mean difference (SMD) of women compared with men.
The results are presented with and without correction for multiple
testing. We used the false discovery rate procedure to adjust p-
values for multiple testing [33].
Results
Sample description
The sample of the present study consisted of 343 ARMS patients
(185 men, 158 women) and 67 HC subjects (34 men, 33 women).
Sociodemographic and clinical characteristics of our sample are
presented in Table 1. Cannabis use was more frequent in male
ARMS patients than female ARMS patients (30.51% vs. 18.46%
used cannabis at least a few times per year). With regard to
comorbid affective and anxiety disorders, female ARMS patients
showed more often a current anxiety disorder as well as posttrau-
matic stress disorders (PTSD) compared withmale ARMS patients.
There were no significant sex differences regarding any current
affective disorder (i.e., current depressive, manic, or hypomanic
episode and dysthymic disorder), neither for ARMS nor for
HC.With regard to psychopathology, male ARMS patients showed
significantly more severe BPRS “negative symptoms” (p=0.006)
than female ARMS patients. There were no sex differences in
ARMS and HC with regard to age, years of education, current
psychiatric medication, global functioning, BPRS “positive symp-
toms” and BPRS “total score.”
Effects of sex and diagnostic group on cognitive functioning
Means and standard deviations (SD) of the total group, ARMS, and
HC are presented in Table 2. Table 3 shows the results of the mixed
effects models using neurocognitive performance as the continuous
dependent variable and sex as well as group (ARMS, HC) as fixed
effects factors. SMDs of the neuropsychological measures are addi-
tionally presented in Figure 1.
In the combined sample of ARMS and HC, women recognized
more angry faces in the “Degraded Faces Affect Recognition” social
cognition task (p=0.034, b= 0.25), performed better in the “Digital
Symbol Coding” speed of processing task (p≤ 0.001, b=0.44) of the
WAIS-III, and remembered more words in the “Rey Auditory
Verbal Learning Test (RAVLT) delayed recall” (p=0.003, b=
0.41) and “RAVLT trials 1 to 5” (p=0.001, b=0.40) than men.
However, after correction for multiple testing, only the differences
in “Digital Symbol Coding” and the RAVLT measures remained
statistically significant.
Effects of diagnostic group are presented in Table 3. ARMS
patients performed significantly worse in all cognitive performance
scores, except in all scores of the problem solving and social
cognition tasks.
There was one statistically significant interaction between sex
and group (ARMS, HC) on the “WAIS-III Digit Span Backwards”
working memory task (p=0.011), which was due to a significantly
better performance of female HC compared with male HC (p<
0.026, b=0.59) and a nonsignificantly worse performance of
female ARMS patients compared with male ARMS patients (p=
0.186, b=0.16). However, this sex  group interaction was no
longer significant after correction for multiple testing.
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The results did not change, when age or frequent cannabis use
(i.e., at least several times per week) were included as covariates.
Discussion
To the best of our knowledge, this is the first study investigating sex-
related neurocognitive performance differences in a multinational
ARMS sample of this size, using a comprehensive neuropsycholog-
ical battery and a healthy comparison group. In line with our
hypotheses, women showed superior performance in the domain
of verbal learning and memory independent of whether they were
ARMS patients orHC. Furthermore, women outperformedmen on
measures of speed of processing (i.e., Digital Symbol Coding total
raw score) and social cognition (i.e., Degraded Facial Affect Rec-
ognition Task (DFAR) angry faces total correct), whereas men
outperformed women on a trend-wise level on a task of working
memory (i.e., arithmetic total raw score). Additionally, our results
show that ARMS patients displayed alterations in attention, current
IQ, speed of processing, verbal learning, and working memory
compared with HC. However, we will not discuss this aspect any
further since it is not the focal point of the present study.
Finally, we found a sex group interaction effect on working
memory (i.e., WAIS-III Digit Span Backwards), which was due to
a significantly better performance of female HC compared with
male HC and a nonsignificantly better performance of male
ARMS patients compared with female ARMS patients. However,
Table 1. Sociodemographic and clinical sample characteristics
ARMS HC
All Men Women p value
N
All Men Women p value
N(n = 343) (n = 185) (n = 158) (n = 67) (n = 34) (n = 33)
Age 22.4 (4.91) 22.7 (5.08) 22.1 (4.70) 0.210 343 22.9 (4.09) 23.0 (4.09) 22.7 (4.15) 0.720 67
Ethnicity 0.481 342 0.009** 67
White 245 (71.6%) 136 (73.5%) 109 (69.4%) 42 (62.7%) 23 (67.6%) 19 (57.6%)
Black 34 (9.94%) 18 (9.73%) 16 (10.2%) 10 (14.9%) 8 (23.5%) 2 (6.06%)
Mixed 28 (8.19%) 16 (8.65%) 12 (7.64%) 6 (8.96%) 0 (0.0%) 6 (18.2%)
Asian 11 (3.22%) 6 (3.24%) 5 (3.18%) 9 (13.4%) 3 (8.82%) 6 (18.2%)
North African 12 (3.51%) 6 (3.24%) 6 (3.82%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Other 12 (3.51%) 3 (1.62%) 9 (5.73%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Years of education 14.4 (3.07) 14.4 (3.28) 14.4 (2.83) 0.989 302 16.1 (2.79) 16.6 (2.97) 15.6 (2.55) 0.169 65
Cannabis current frequency 0.029* 334 0.081 67
None 247 (74.0%) 121 (68.4%) 126 (80.3%) 49 (73.1%) 22 (64.7%) 27 (81.8%)
Only once or twice 4 (1.20%) 2 (1.13%) 2 (1.27%) 1 (1.49%) 0 (0.0%) 1 (3.03%)
A few times each year 17 (5.09%) 7 (3.95%) 10 (6.37%) 4 (5.97%) 4 (11.8%) 0 (0.0%)
A few times each month 17 (5.09%) 12 (6.78%) 5 (3.18%) 7 (10.4%) 4 (11.8%) 3 (9.09%)
(More than) once a week 11 (3.29%) 9 (5.08%) 2 (1.27%) 3 (4.48%) 1 (2.94%) 2 (6.06%)
Every day 38 (11.4%) 26 (14.7%) 12 (7.64%) 3 (4.48%) 3 (8.82%) 0 (0.0%)
Antipsychotics currently 30 (11.8%) 15 (11.6%) 15 (11.9%) 1.000 255 0 (0.0%) 0 (0.0%) 0 (0.0%) 56
Antidepressants currently 82 (32.2%) 39 (30.2%) 43 (34.1%) 0.595 255 2 (3.57%) 0 (0.0%) 2 (7.14%) 0.491 56
Sedatives currently 15 (5.88%) 7 (5.43%) 8 (6.35%) 0.963 255 1 (1.79%) 0 (0.0%) 1 (3.57%) 1.000 56
Current affective disorder 127 (37.0%) 60 (32.4%) 67 (42.4%) 0.073 343 0 (0.0%) 0 (0.0%) 0 (0.0%) 67
Current anxiety disorder 166 (48.4%) 73 (39.5%) 93 (58.9%) 0.001** 343 5 (7.46%) 2 (5.88%) 3 (9.09%) 0.673 67
Current OCD 29 (9.70%) 16 (10.1%) 13 (9.29%) 0.975 299 0 (0.0%) 0 (0.0%) 0 (0.0%) 53
Current PTSD 34 (10.6%) 11 (6.40%) 23 (15.4%) 0.015* 321 0 (0.0%) 0 (0.0%) 0 (0.0%) 65
GAF disability, impairment 55.5 (12.3) 55.8 (12.4) 55.1 (12.1) 0.584 331 85.0 (8.98) 85.2 (8.15) 84.7 (9.92) 0.819 66
BPRS positive symptoms 7.48 (3.17) 7.67 (3.28) 7.27 (3.03) 0.254 323 3.17 (0.53) 3.13 (0.43) 3.21 (0.63) 0.550 59
BPRS negative symptoms 5.05 (2.40) 5.38 (2.65) 4.66 (2.02) 0.006** 324 3.00 (0.00) 3.00 (0.00) 3.00 (0.00) 0.325 59
BPRS total score 43.6 (10.2) 44.1 (10.6) 43.0 (9.67) 0.361 324 25.4 (2.61) 25.3 (2.24) 25.6 (3.01) 0.618 59
Abbreviations: ARMS, at-risk mental state; BPRS, Brief Psychiatric Rating Scale; GAF, Global Assessment of Functioning; HC, healthy controls; OCD, obsessive–compulsive disorder; PTSD, post-
traumatic stress disorder.
Continuous variables are described by means and standard deviation in brackets.
*p < 0.05.
**p < 0.01.
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only sex differences in the total group in speed of processing and
verbal learning remained significant after correction for multiple
testing.
With regard to verbal learning andmemory, our finding that the
female advantage is equally present in ARMS patients as in HC is in
line with previous research [1,15]. Furthermore, it corroborates the
findings of an earlier study of our own group that reported no
interaction effect between diagnostic group (i.e., ARMS, FEP, HC)
and verbal learning and memory [10].
Regarding processing speed, our finding that women perform
better than men is also consistent with earlier findings from the
general population [34,35] and patients with schizophrenia
[36,37]. To the best of our knowledge, this is the first study examining
sex differences in ARMS and healthy subjects by using well-
established tests to evaluate processing speed (i.e., TrailMaking Test,
WAIS-III Digit Symbol subtest). A previous study has investigated
sex-related cognitive performance differences inARMS, FEP andHC
but did not include tests specifically measuring processing speed
[10]. However, the authors found a shorter reaction time for men in
the working memory task independent of diagnostic group. They
explain the findings by a superior working memory performance
rather than generally enhanced processing speed in men as no sex
differences in reaction timeduring theContinuousPerformanceTest
and the Go/No-Go subtest of the Test of Attentional Performance
(TAP) were detected, while maintaining a comparable overall work-
ing memory performance level [10].
Table 2. Means and standard deviations of neuropsychological test data in ARMS patients and HC
Total group ARMS HC
All Men Women All Men Women All Men Women
(n = 410) (n = 219) (n = 191) (n = 343) (n = 185) (n = 158) (n = 67) (n = 34) (n = 33)
Attention
WAIS-III Digit Span Forward 9.69 (2.26) 9.66 (2.19) 9.73 (2.34) 9.51 (2.20) 9.50 (2.16) 9.51 (2.24) 10.7 (2.35) 10.5 (2.18) 11.0 (2.57)
Current IQ
Block Design total raw score 43.8 (15.2) 44.8 (15.2) 42.7 (15.3) 42.7 (15.5) 43.8 (15.1) 41.4 (15.8) 49.3 (12.9) 49.7 (14.8) 48.9 (11.0)
Estimate of total IQ 101 (17.9) 102 (18.7) 100 (17.0) 98.6 (16.8) 99.9 (17.6) 97.2 (15.9) 113 (18.1) 112 (20.5) 113 (15.7)
Information total raw score 16.9 (6.56) 17.5 (6.56) 16.2 (6.51) 16.3 (6.73) 17.1 (6.71) 15.5 (6.68) 19.4 (4.98) 19.4 (5.47) 19.4 (4.52)
Problem solving
Beads task draws to decision 6.62 (4.63) 6.90 (5.06) 6.31 (4.11) 6.54 (4.70) 6.74 (5.20) 6.33 (4.09) 7.02 (4.29) 7.73 (4.21) 6.22 (4.32)
Social cognition
BFR total correct 22.3 (2.33) 22.3 (2.24) 22.3 (2.43) 22.2 (2.32) 22.3 (2.24) 22.2 (2.42) 22.6 (2.36) 22.1 (2.31) 23.1 (2.36)
DFAR angry faces total
correct
10.2 (4.90) 9.67 (4.90) 10.7 (4.84) 10.5 (4.71) 9.99 (4.79) 11.0 (4.58) 8.61 (5.53) 7.94 (5.23) 9.30 (5.82)
DFAR frightened faces total
correct
8.59 (4.25) 8.17 (4.21) 9.07 (4.26) 8.80 (4.09) 8.26 (4.09) 9.43 (4.02) 7.50 (4.89) 7.68 (4.85) 7.31 (5.01)
DFAR happy faces total
correct
12.8 (5.08) 12.5 (5.23) 13.1 (4.89) 13.1 (4.78) 12.7 (5.07) 13.5 (4.38) 11.3 (6.23) 11.4 (6.01) 11.1 (6.54)
DFAR neutral faces total
correct
11.4 (4.84) 11.1 (4.95) 11.6 (4.72) 11.6 (4.57) 11.3 (4.76) 12.0 (4.31) 10.2 (5.97) 10.6 (5.92) 9.81 (6.09)
Speed of processing
Digital Symbol Coding total
raw score
73.1 (16.1) 70.2 (16.6) 76.4 (15.0) 71.7 (15.8) 69.2 (16.6) 74.5 (14.4) 80.1 (15.9) 75.2 (15.9) 85.0 (14.6)
TMT-A time to completion 29.6 (12.3) 30.7 (13.9) 28.4 (10.1) 30.2 (12.2) 31.2 (13.6) 29.1 (10.3) 26.6 (12.8) 28.1 (15.6) 25.0 (8.62)
TMT-B time to completion 70.3 (29.4) 74.6 (30.8) 65.7 (27.2) 73.2 (30.4) 77.9 (31.6) 68.0 (28.2) 56.3 (18.8) 58.0 (19.5) 54.4 (18.2)
Verbal learning
RAVLT delayed recall correct 10.7 (3.14) 10.2 (3.31) 11.4 (2.79) 10.6 (3.05) 10.0 (3.21) 11.2 (2.72) 11.4 (3.48) 10.9 (3.76) 12.0 (3.09)
RAVLT trial 1 correct 6.82 (2.02) 6.58 (1.93) 7.09 (2.09) 6.69 (1.99) 6.45 (1.86) 6.98 (2.11) 7.43 (2.04) 7.25 (2.14) 7.64 (1.93)
RAVLT trials 1–5 correct 52.2 (9.91) 50.6 (9.68) 54.0 (9.88) 51.3 (9.98) 49.9 (9.64) 53.1 (10.1) 56.3 (8.50) 54.1 (9.20) 58.7 (7.01)
Working memory
Arithmetic total raw score 13.5 (4.76) 14.1 (4.68) 12.8 (4.76) 13.1 (4.70) 13.8 (4.64) 12.3 (4.65) 15.5 (4.58) 15.9 (4.60) 15.1 (4.60)
WAIS-III Digit Span
Backwards
6.73 (2.27) 6.74 (2.28) 6.71 (2.27) 6.60 (2.19) 6.72 (2.30) 6.46 (2.06) 7.44 (2.58) 6.87 (2.21) 8.17 (2.87)
Abbreviations: ARMS, at-risk mental state; BFR, Benton Facial Recognition Test; DFAR, Degraded Facial Affect Recognition Task; HC, healthy controls; RAVLT, Rey Auditory Verbal Learning Test;
TMT, Trail Making Test; WAIS, Wechsler Adult Intelligence Scale.
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A strength of our study is that we examined sex differences
with well-established tests using the classification of the
MATRICS panel [22,38]. As the MCCB domains are well known
in schizophrenia research, this may help future studies to compare
sex-related cognitive performance differences in ARMS and
schizophrenic patients. Furthermore, this is the first study to
investigate sex differences in cognitive functioning in an ARMS
sample of this size.
However, there are some limitations to the present study that
need to be acknowledged. Our neuropsychological test battery was
originally selected to identify genetic and environmental interac-
tions in psychosis and not specifically to detect sex differences.
Accordingly, the test battery did not include other sensitive tasks
to detect sex differences such as visuo-spatial tasks. Additionally,
the domain of visual learning in the MATRICS consensus battery
was not covered. Furthermore, our control group was rather small
in comparison to the ARMS group, which reduced the statistical
power to detect interaction effects between sex and group. Finally,
it is important to note that sex-related cognitive performance
differences depend on a wide variety of conditions, for example,
the severity of symptoms and especially the fluctuation of estrogen
levels during the menstrual cycle in women (for review, see
reference [1]). There is evidence that high levels of estrogen at
the mid-luteal point are associated with better verbal memory and
diminished spatial ability [39]. Thus, it is possible that some
effects would have changed if we had measured women at a
specific time point during their monthly cycle. Unfortunately, in
our study no assessment of the time point during the monthly
cycle was performed.
Taken together, our findings indicate that sex differences in
cognitive functioning in ARMS patients are very similar to those
seen in the general population and in schizophrenia patients.
Table 3. p values and coefficients of fixed effects of mixed effects models
Group Sex Group sex
p value p value corra Coef p value p value corra Coef p value p value corra Coef
Attention
WAIS-III Digit Span Forward <0.001*** 0.002** 0.55 0.441 0.530 0.11 0.467 0.782 0.22
Current IQ
Block Design total raw score <0.001*** <0.001*** 0.59 0.364 0.505 0.12 0.561 0.782 0.15
Estimate of total IQ <0.001*** <0.001*** 0.88 0.658 0.697 0.06 0.385 0.782 0.22
Information total raw score <0.001*** <0.001*** 0.61 0.329 0.493 0.13 0.277 0.774 0.29
Problem solving
Beads task draws to decision 0.331 0.426 0.15 0.098 0.252 0.23 0.659 0.782 0.13
Social cognition
BFR total correct 0.143 0.198 0.22 0.201 0.329 0.18 0.124 0.705 0.45
DFAR angry faces total correct 0.435 0.489 0.10 0.034* 0.151 0.25 0.695 0.782 0.09
DFAR frightened faces total correct 0.421 0.489 0.11 0.409 0.525 0.10 0.112 0.705 0.40
DFAR happy faces total correct 0.531 0.563 0.08 0.547 0.615 0.07 0.301 0.774 0.24
DFAR neutral faces total correct 0.922 0.922 0.01 0.922 0.922 0.01 0.266 0.774 0.27
Speed of processing
Digital Symbol Coding total raw score <0.001*** <0.001*** 0.63 <0.001*** 0.011* 0.44 0.157 0.705 0.37
TMT-A time to completion 0.017* 0.028* 0.36 0.162 0.291 0.20 0.549 0.782 0.17
TMT-B time to completion <0.001*** <0.001*** 0.65 0.122 0.261 0.21 0.641 0.782 0.13
Verbal learning
RAVLT delayed recall correct 0.026* 0.040* 0.33 0.003** 0.019* 0.41 0.936 0.936 0.02
RAVLT trial 1 correct 0.016* 0.028* 0.34 0.069 0.206 0.24 0.874 0.926 0.04
RAVLT trials 1–5 correct <0.001*** <0.001*** 0.49 0.001** 0.011* 0.40 0.593 0.782 0.13
Working memory
Arithmetic total raw score <0.001*** <0.001*** 0.60 0.064 0.206 0.24 0.580 0.782 0.14
WAIS-III Digit Span Backwards <0.001*** 0.002** 0.51 0.130 0.261 0.22 0.011* 0.197 0.75
Abbreviations: BFR, Benton Facial Recognition Test; coef, y-standardized regression coefficients of fixed effects; DFAR, Degraded Facial Affect Recognition Task; RAVLT, Rey Auditory Verbal
Learning Test; TMT, Trail Making Test; WAIS, Wechsler Adult Intelligence Scale.
aCorrected for multiple testing using Benjamini–Hochberg method.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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Figure 1. Cognitive performance of women compared with men in at-risk mental state for psychosis individuals and healthy controls. The dotted horizontal line at zero represents
the performance of men. Differences are expressed in units of standard deviation and are significant if the 95% confidence interval (vertical line) does not overlap with zero.
Variables with a minus sign were reversed so that positive scores always represent good performance. Abbreviations: RAVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making
Test; WAIS, Wechsler Adult Intelligence Scale.
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